Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: Pre-market Movers » 08:56
11/23/22
11/23
08:56
11/23/22
08:56
TSLA

Tesla

$169.91 /

+2.04 (+1.22%)

, MANU

Manchester United

$14.88 /

+1.83 (+14.02%)

, DE

Deere

$416.60 /

+4.53 (+1.10%)

, HPQ

HP Inc.

$29.37 /

+0.205 (+0.70%)

, JWN

Nordstrom

$22.65 /

+1.39 (+6.54%)

, ADSK

Autodesk

$208.40 /

+1.79 (+0.87%)

, GES

Guess

$19.74 /

+0.32 (+1.65%)

, CS

Credit Suisse

$4.09 /

-0.06 (-1.45%)

, MGNX

MacroGenics

$6.19 /

-0.185 (-2.90%)

Check out this morning's…

ShowHide Related Items >><<
TSLA Tesla
$169.91 /

+2.04 (+1.22%)

MGNX MacroGenics
$6.19 /

-0.185 (-2.90%)

MANU Manchester United
$14.88 /

+1.83 (+14.02%)

JWN Nordstrom
$22.65 /

+1.39 (+6.54%)

HPQ HP Inc.
$29.37 /

+0.205 (+0.70%)

GES Guess
$19.74 /

+0.32 (+1.65%)

DE Deere
$416.60 /

+4.53 (+1.10%)

CS Credit Suisse
$4.09 /

-0.06 (-1.45%)

ADSK Autodesk
$208.40 /

+1.79 (+0.87%)

TSLA Tesla
$169.91 /

+2.04 (+1.22%)

11/23/22 Morgan Stanley
Morgan Stanley wonders if 'value opportunity emerging' in Tesla after selloff
11/23/22 Citi
Tesla upgraded to Neutral from Sell at Citi
11/10/22 Wedbush
Tesla removed from 'Best Ideas' list at Wedbush
11/02/22 Bernstein
Bernstein analysis shows Tesla total software run rate revenues of $290M/quarter
MANU Manchester United
$14.88 /

+1.83 (+14.02%)

11/23/22 Jefferies
Jefferies expects 'competitive process' for Manchester United
06/02/22 Deutsche Bank
Manchester United undervalued after selloff, says Deutsche Bank
03/21/22 Deutsche Bank
Manchester United upgraded on 'value disconnect' at Deutsche Bank
03/21/22 Deutsche Bank
Manchester United upgraded to Buy from Hold at Deutsche Bank
DE Deere
$416.60 /

+4.53 (+1.10%)

11/17/22 Deutsche Bank
Deere price target raised to $374 from $365 at Deutsche Bank
11/14/22 DA Davidson
DA Davidson sees positive trends for Deere into 'at least 2024'
10/26/22 OTR Global
Farm equipment maker view downgraded to Negative from Mixed at OTR Global
10/13/22 Deutsche Bank
Deere price target lowered to $365 from $389 at Deutsche Bank
HPQ HP Inc.
$29.37 /

+0.205 (+0.70%)

11/23/22 Evercore ISI
Evercore sticking with In Line rating on HP Inc. as company takes 'right steps'
11/23/22 Citi
HP Inc. restructuring 'unexpected major positive,' says Citi
11/23/22 Barclays
HP Inc. price target lowered to $24 from $27 at Barclays
11/18/22 BofA
HP Inc. price target lowered to $27 from $30 at BofA
JWN Nordstrom
$22.65 /

+1.39 (+6.54%)

11/14/22 Deutsche Bank
Nordstrom price target lowered to $22 from $23 at Deutsche Bank
09/16/22 Jefferies
Liverpool buying stake 'vote of confidence' in Nordstrom, says Jefferies
09/15/22 Jefferies
Nordstrom assumed with Buy from Hold at Jefferies
08/25/22 Barclays
Nordstrom price target lowered to $18 from $21 at Barclays
ADSK Autodesk
$208.40 /

+1.79 (+0.87%)

11/23/22 Stifel
Autodesk price target lowered to $220 from $270 at Stifel
11/23/22 Baird
Autodesk price target lowered to $244 from $255 at Baird
11/23/22 BofA
Autodesk price target lowered to $225 from $240 at BofA
11/23/22 Mizuho
Autodesk downgraded to Neutral from Buy at Mizuho
GES Guess
$19.74 /

+0.32 (+1.65%)

05/26/22 B. Riley
Guess price target lowered to $29 from $36 at B. Riley
03/17/22 B. Riley
Guess price target lowered to $36 from $38 at B. Riley
11/30/21 Jefferies
Guess assumed with a Buy at Jefferies
CS Credit Suisse
$4.09 /

-0.06 (-1.45%)

11/07/22 AlphaValue/Baader
Credit Suisse downgraded to Sell from Buy at AlphaValue/Baader
10/28/22 JPMorgan
Credit Suisse price target lowered to CHF 5.50 from CHF 6 at JPMorgan
10/06/22 JPMorgan
Credit Suisse upgraded to Neutral from Underweight at JPMorgan
10/05/22 Societe Generale
Credit Suisse price target lowered to CHF 4.20 from CHF 5.50 at Societe Generale
MGNX MacroGenics
$6.19 /

-0.185 (-2.90%)

11/23/22 Citi
MacroGenics downgraded to Neutral from Buy at Citi
11/22/22 Guggenheim
MacroGenics upgraded to Buy at Guggenheim ahead of near-term catalysts
11/22/22 Guggenheim
MacroGenics upgraded to Buy from Neutral at Guggenheim
11/22/22 Cowen
MacroGenics downgraded to Market Perform from Outperform at Cowen
TSLA Tesla
$169.91 /

+2.04 (+1.22%)

MGNX MacroGenics
$6.19 /

-0.185 (-2.90%)

MANU Manchester United
$14.88 /

+1.83 (+14.02%)

JWN Nordstrom
$22.65 /

+1.39 (+6.54%)

HPQ HP Inc.
$29.37 /

+0.205 (+0.70%)

GES Guess
$19.74 /

+0.32 (+1.65%)

DE Deere
$416.60 /

+4.53 (+1.10%)

CS Credit Suisse
$4.09 /

-0.06 (-1.45%)

ADSK Autodesk
$208.40 /

+1.79 (+0.87%)

TSLA Tesla
$169.91 /

+2.04 (+1.22%)

MANU Manchester United
$14.88 /

+1.83 (+14.02%)

JWN Nordstrom
$22.65 /

+1.39 (+6.54%)

HPQ HP Inc.
$29.37 /

+0.205 (+0.70%)

DE Deere
$416.60 /

+4.53 (+1.10%)

CS Credit Suisse
$4.09 /

-0.06 (-1.45%)

ADSK Autodesk
$208.40 /

+1.79 (+0.87%)

TSLA Tesla
$169.91 /

+2.04 (+1.22%)

MANU Manchester United
$14.88 /

+1.83 (+14.02%)

JWN Nordstrom
$22.65 /

+1.39 (+6.54%)

HPQ HP Inc.
$29.37 /

+0.205 (+0.70%)

GES Guess
$19.74 /

+0.32 (+1.65%)

DE Deere
$416.60 /

+4.53 (+1.10%)

CS Credit Suisse
$4.09 /

-0.06 (-1.45%)

ADSK Autodesk
$208.40 /

+1.79 (+0.87%)

TSLA Tesla
$169.91 /

+2.04 (+1.22%)

MANU Manchester United
$14.88 /

+1.83 (+14.02%)

JWN Nordstrom
$22.65 /

+1.39 (+6.54%)

HPQ HP Inc.
$29.37 /

+0.205 (+0.70%)

GES Guess
$19.74 /

+0.32 (+1.65%)

DE Deere
$416.60 /

+4.53 (+1.10%)

CS Credit Suisse
$4.09 /

-0.06 (-1.45%)

ADSK Autodesk
$208.40 /

+1.79 (+0.87%)

Downgrade
MacroGenics downgraded to Neutral from Buy at Citi » 05:16
11/23/22
11/23
05:16
11/23/22
05:16
MGNX

MacroGenics

$6.19 /

-0.185 (-2.90%)

Citi analyst Yigal…

Citi analyst Yigal Nochomovitz downgraded MacroGenics to Neutral from Buy with a price target of $7, down from $16, after removing enoblituzumab in squamous cell carcinoma of the head and neck cancer and non small cell lung cancer from his model. With currently no ongoing or planned MacroGenics-sponsored studies using enoblituzumab, combined with the company's efforts to preserve its cash runway, future enoblituzumab potential should not be reflected in the stock's base case, Nochomovitz tells investors in a research note. The analyst continues to have a favorable view on MGC018 in metastatic castrate-resistant prostate cancer but believes the market is appropriately pricing in the risk/reward for the program. MacroGenics also lacks significant near-term data catalysts, contends Nochomovitz.

ShowHide Related Items >><<
MGNX MacroGenics
$6.19 /

-0.185 (-2.90%)

MGNX MacroGenics
$6.19 /

-0.185 (-2.90%)

11/22/22 Guggenheim
MacroGenics upgraded to Buy at Guggenheim ahead of near-term catalysts
11/22/22 Guggenheim
MacroGenics upgraded to Buy from Neutral at Guggenheim
11/22/22 Cowen
MacroGenics downgraded to Market Perform from Outperform at Cowen
11/14/22 BMO Capital
MacroGenics upgraded to Outperform from Market Perform at BMO Capital
MGNX MacroGenics
$6.19 /

-0.185 (-2.90%)

Over a week ago
Upgrade
MacroGenics upgraded to Buy at Guggenheim ahead of near-term catalysts » 16:22
11/22/22
11/22
16:22
11/22/22
16:22
MGNX

MacroGenics

$6.19 /

-0.185 (-2.90%)

, GILD

Gilead

$85.23 /

+0.865 (+1.03%)

, PRVB

Provention Bio

$8.89 /

+1.135 (+14.64%)

Guggenheim analyst…

Guggenheim analyst Charles Zhu upgraded MacroGenics (MGNX) to Buy from Neutral with a $12 price target ahead of near-term clinical data catalysts. Management told him they were encouraged by emerging lorigerlimab data that are on-track for a potential presentation at a medical conference in Q1 2023 and that MGC018 combination cohorts on the Q4W schedule continue to dose-escalation with a possible initial readout as early as the second half of 2023, Zhu tells investors. In addition, recent partnerships with Gilead (GILD) and Provention Bio (PRVB) have strengthened MacroGenics' balance sheet to extend its cash runway through year-end 2024, Zhu said.

ShowHide Related Items >><<
PRVB Provention Bio
$8.89 /

+1.135 (+14.64%)

MGNX MacroGenics
$6.19 /

-0.185 (-2.90%)

GILD Gilead
$85.23 /

+0.865 (+1.03%)

MGNX MacroGenics
$6.19 /

-0.185 (-2.90%)

11/22/22 Guggenheim
MacroGenics upgraded to Buy from Neutral at Guggenheim
11/22/22 Cowen
MacroGenics downgraded to Market Perform from Outperform at Cowen
11/14/22 BMO Capital
MacroGenics upgraded to Outperform from Market Perform at BMO Capital
11/07/22 H.C. Wainwright
MacroGenics price target raised to $12 from $11 at H.C. Wainwright
GILD Gilead
$85.23 /

+0.865 (+1.03%)

11/09/22 Argus
Gilead price target raised to $100 from $70 at Argus
11/08/22 Cowen
Gilead price target raised to $90 from $80 at Cowen
11/08/22 Mizuho
Gilead price target raised to $88 from $75 at Mizuho
11/01/22 Guggenheim
AnaptysBio upgraded to Buy at Guggenheim on checkpoint agonist opportunity
PRVB Provention Bio
$8.89 /

+1.135 (+14.64%)

11/19/22 Chardan
Provention Bio price target raised to $30 from $24 at Chardan
11/18/22 Jefferies
Provention Bio price target raised to $22 from $18 at Jefferies
10/06/22 Jefferies
Provention Bio price target raised to $15 from $10 at Jefferies
10/06/22 Chardan
Provention co-promotion deal reinforces Chardan's confidence in teplizumab
PRVB Provention Bio
$8.89 /

+1.135 (+14.64%)

MGNX MacroGenics
$6.19 /

-0.185 (-2.90%)

GILD Gilead
$85.23 /

+0.865 (+1.03%)

PRVB Provention Bio
$8.89 /

+1.135 (+14.64%)

GILD Gilead
$85.23 /

+0.865 (+1.03%)

PRVB Provention Bio
$8.89 /

+1.135 (+14.64%)

GILD Gilead
$85.23 /

+0.865 (+1.03%)

Upgrade
MacroGenics upgraded to Buy from Neutral at Guggenheim » 16:19
11/22/22
11/22
16:19
11/22/22
16:19
MGNX

MacroGenics

$6.19 /

-0.185 (-2.90%)

Guggenheim analyst…

Guggenheim analyst Charles Zhu upgraded MacroGenics to Buy from Neutral with a $12 price target.

ShowHide Related Items >><<
MGNX MacroGenics
$6.19 /

-0.185 (-2.90%)

MGNX MacroGenics
$6.19 /

-0.185 (-2.90%)

11/22/22 Cowen
MacroGenics downgraded to Market Perform from Outperform at Cowen
11/14/22 BMO Capital
MacroGenics upgraded to Outperform from Market Perform at BMO Capital
11/07/22 H.C. Wainwright
MacroGenics price target raised to $12 from $11 at H.C. Wainwright
10/18/22 H.C. Wainwright
MacroGenics price target raised to $11 from $10 at H.C. Wainwright
MGNX MacroGenics
$6.19 /

-0.185 (-2.90%)

Downgrade
MacroGenics downgraded to Market Perform from Outperform at Cowen » 05:58
11/22/22
11/22
05:58
11/22/22
05:58
MGNX

MacroGenics

$6.39 /

-0.09 (-1.39%)

Cowen analyst Boris…

Cowen analyst Boris Peaker downgraded MacroGenics to Market Perform from Outperform without a price target. Margenza sales "remain insignificant" and the TAMARACK study is "risky" with no near-term milestones, Peaker tells investors in a research note.

ShowHide Related Items >><<
MGNX MacroGenics
$6.39 /

-0.09 (-1.39%)

MGNX MacroGenics
$6.39 /

-0.09 (-1.39%)

11/14/22 BMO Capital
MacroGenics upgraded to Outperform from Market Perform at BMO Capital
11/07/22 H.C. Wainwright
MacroGenics price target raised to $12 from $11 at H.C. Wainwright
10/18/22 H.C. Wainwright
MacroGenics price target raised to $11 from $10 at H.C. Wainwright
09/12/22 H.C. Wainwright
MacroGenics price target lowered to $10 from $35 at H.C. Wainwright
MGNX MacroGenics
$6.39 /

-0.09 (-1.39%)

Initiation
Truist starts ImmunoGen at Buy, sees share boost from full approval for Elahere » 07:28
11/21/22
11/21
07:28
11/21/22
07:28
IMGN

ImmunoGen

$5.23 /

+0.07 (+1.36%)

Truist analyst Asthika…

Truist analyst Asthika Goonewarden initiated coverage of ImmunoGen with a Buy rating and $10 price target. The stock has reacted negatively to its very recent maiden conditional approval, which suggests that investors are still concerned that the confirmatory trial will fail, but the company is on the home stretch and will ultimately prevail in receiving full approval for Elahere, the analyst tells investors in a research note. This should unshackle ImmunoGen shares, Goonewarden adds, also stating that circumstances have left a second ADC "overlooked".

ShowHide Related Items >><<
IMGN ImmunoGen
$5.23 /

+0.07 (+1.36%)

IMGN ImmunoGen
$5.23 /

+0.07 (+1.36%)

11/21/22 Truist
ImmunoGen initiated with a Buy at Truist
11/16/22 Canaccord
ImmunoGen price target raised to $15 from $12 at Canaccord
11/16/22 H.C. Wainwright
ImmunoGen price target raised to $20 from $12 at H.C. Wainwright
11/15/22 Piper Sandler
ImmunoGen approval 'best case scenario,' says Piper Sandler
IMGN ImmunoGen
$5.23 /

+0.07 (+1.36%)

  • 02
    Dec
Hot Stocks
ImmunoGen names Daniel Char as Senior Vice President and Chief Legal Officer » 06:34
11/21/22
11/21
06:34
11/21/22
06:34
IMGN

ImmunoGen

$5.23 /

+0.07 (+1.36%)

, EVLO

Evelo Biosciences

$2.08 /

-0.05 (-2.35%)

Char joins ImmunoGen…

Char joins ImmunoGen (IMGN) from Evelo Biosciences (EVLO) where he served as General Counsel and Secretary providing strategic counsel and operational support on a broad range of business and legal issues, including business development, commercialization, healthcare fraud, and intellectual property.

ShowHide Related Items >><<
IMGN ImmunoGen
$5.23 /

+0.07 (+1.36%)

EVLO Evelo Biosciences
$2.08 /

-0.05 (-2.35%)

IMGN ImmunoGen
$5.23 /

+0.07 (+1.36%)

11/21/22 Truist
ImmunoGen initiated with a Buy at Truist
11/16/22 Canaccord
ImmunoGen price target raised to $15 from $12 at Canaccord
11/16/22 H.C. Wainwright
ImmunoGen price target raised to $20 from $12 at H.C. Wainwright
11/15/22 Piper Sandler
ImmunoGen approval 'best case scenario,' says Piper Sandler
EVLO Evelo Biosciences
$2.08 /

-0.05 (-2.35%)

11/16/22 Chardan
Evelo Biosciences downgraded to Neutral from Buy at Chardan
08/15/22 Chardan
Evelo Biosciences price target lowered to $5 from $12 at Chardan
IMGN ImmunoGen
$5.23 /

+0.07 (+1.36%)

EVLO Evelo Biosciences
$2.08 /

-0.05 (-2.35%)

  • 02
    Dec
Initiation
ImmunoGen initiated with a Buy at Truist » 06:27
11/21/22
11/21
06:27
11/21/22
06:27
IMGN

ImmunoGen

$5.23 /

+0.07 (+1.36%)

Truist analyst Asthika…

Truist analyst Asthika Goonewarden initiated coverage of ImmunoGen with a Buy rating and $10 price target.

ShowHide Related Items >><<
IMGN ImmunoGen
$5.23 /

+0.07 (+1.36%)

IMGN ImmunoGen
$5.23 /

+0.07 (+1.36%)

11/16/22 Canaccord
ImmunoGen price target raised to $15 from $12 at Canaccord
11/16/22 H.C. Wainwright
ImmunoGen price target raised to $20 from $12 at H.C. Wainwright
11/15/22 Piper Sandler
ImmunoGen approval 'best case scenario,' says Piper Sandler
11/15/22 Barclays
ImmunoGen price target raised to $9 from $8 at Barclays
IMGN ImmunoGen
$5.23 /

+0.07 (+1.36%)

  • 02
    Dec
Hot Stocks
NeoGenomics, ImmunoGen launche new program for ovarian cancer patients » 09:24
11/18/22
11/18
09:24
11/18/22
09:24
NEO

NeoGenomics

$9.97 /

-1.17 (-10.51%)

, IMGN

ImmunoGen

$5.16 /

-0.02 (-0.39%)

NeoGenomics (NEO)…

NeoGenomics (NEO) launched a novel biomarker testing program for patients with epithelial ovarian cancer, including primary peritoneal or fallopian tube cancers. Through the FR-ASSIST program, sponsored by ImmunoGen, Inc., (IMGN), EOC patients will have access to the FOLR1 IHC CDx test performed by NeoGenomics to measure the expression of a protein called folate receptor alpha. The FR-ASSIST program was launched in conjunction with the recent U.S. Food and Drug Administration's approval of ELAHERE, ImmunoGen's antibody-drug conjugate targeting FRalpha in patients with platinum-resistant EOC. The new testing program is sponsored entirely by ImmunoGen and provides eligible EOC patients with FRalpha-expression testing through NeoGenomics at no cost, regardless of insurance coverage or test results.

ShowHide Related Items >><<
NEO NeoGenomics
$9.97 /

-1.17 (-10.51%)

IMGN ImmunoGen
$5.16 /

-0.02 (-0.39%)

NEO NeoGenomics
$9.97 /

-1.17 (-10.51%)

11/14/22 Piper Sandler
NeoGenomics price target lowered to $18 from $19 at Piper Sandler
08/26/22 Benchmark
NeoGenomics downgraded to Hold from Buy at Benchmark
08/22/22 Needham
Needham cuts NeoGenomics to Hold, sees 2023 as 'transition year'
08/22/22 Needham
NeoGenomics downgraded to Hold from Buy at Needham
IMGN ImmunoGen
$5.16 /

-0.02 (-0.39%)

11/16/22 Canaccord
ImmunoGen price target raised to $15 from $12 at Canaccord
11/16/22 H.C. Wainwright
ImmunoGen price target raised to $20 from $12 at H.C. Wainwright
11/15/22 Piper Sandler
ImmunoGen approval 'best case scenario,' says Piper Sandler
11/15/22 Barclays
ImmunoGen price target raised to $9 from $8 at Barclays
NEO NeoGenomics
$9.97 /

-1.17 (-10.51%)

IMGN ImmunoGen
$5.16 /

-0.02 (-0.39%)

  • 02
    Dec
NEO NeoGenomics
$9.97 /

-1.17 (-10.51%)

Hot Stocks
MacroGenics earns $60M milestone with FDA approval of Teplizumab » 18:10
11/17/22
11/17
18:10
11/17/22
18:10
MGNX

MacroGenics

$6.54 /

-0.185 (-2.75%)

MacroGenics reported that…

MacroGenics reported that the U.S. Food and Drug Administration announced the approval of the Biologics License Application for teplizumab, an anti-CD3 monoclonal antibody that was previously developed by MacroGenics. Teplizumab was acquired by Provention Bio, Inc. in May 2018 pursuant to an asset purchase agreement. "We are very pleased to see the culmination of years of effort by Provention, MacroGenics, and tireless champions in academia and government, with the achievement of the approval of teplizumab," said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. "We applaud this outcome, which represents an advancement for individuals and their families dealing with the risks and consequences of type 1 diabetes." Under the agreement, Provention is obligated to pay MacroGenics contingent milestone payments totaling $170 million upon the achievement of certain regulatory approval milestones, including $60 million for the approval of a BLA for a first indication in the United States. In addition, Provention is obligated to make contingent milestone payments to MacroGenics totaling $225 million upon the achievement of certain sales milestones as well as a single-digit royalty on net sales of the product. Based on MacroGenics' cash, cash equivalents and marketable securities balance as of September 30, 2022, plus projected and anticipated payments from partners, including timely receipt of the milestone payment from Provention, MacroGenics currently anticipates having a cash runway into late 2024.

ShowHide Related Items >><<
MGNX MacroGenics
$6.54 /

-0.185 (-2.75%)

MGNX MacroGenics
$6.54 /

-0.185 (-2.75%)

11/14/22 BMO Capital
MacroGenics upgraded to Outperform from Market Perform at BMO Capital
11/07/22 H.C. Wainwright
MacroGenics price target raised to $12 from $11 at H.C. Wainwright
10/18/22 H.C. Wainwright
MacroGenics price target raised to $11 from $10 at H.C. Wainwright
09/12/22 H.C. Wainwright
MacroGenics price target lowered to $10 from $35 at H.C. Wainwright
MGNX MacroGenics
$6.54 /

-0.185 (-2.75%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.